Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Deals

Takeout premium shows Nestlé’s faith in Aimmune peanut product, despite launch slowed by COVID

By Paul Bonanos, Associate Editor
August 31, 2020 10:00 PM UTC

Nestlé Health Science’s premium-priced takeout of peanut allergy company Aimmune is its biggest move yet in biotech, giving it full control of a marketed program in which the nutrition company had already invested heavily.

The $34.50-per-share acquisition price values Aimmune Therapeutics Inc. (NASDAQ:AIMT) at $2.6 billion, suggesting Nestlé continues to value the biotech’s Palforzia peanut allergen powder-dnfp far more highly than the market has been...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Aimmune Therapeutics Inc.

Nestle Health Science

Nestle S.A.